OPTI-TREX - Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients
The OPTI-TREX study is a research study about children who have had a kidney transplant. Sometimes, after a transplant, tiny blood clots can form in the new kidney, which can stop it from working properly. Doctors often give a medicine called enoxaparin to help prevent these clots. This study is trying to work out the best way to give enoxaparin to each child, so they get exactly the right amount. Researchers are hoping to find a method that ensures the medicine is in the ideal range in the blood, aiming to prevent clotting issues and improve the success of the kidney transplant.
At a glance
What is this study about?
When children receive a new kidney through a transplant, it's a big and important surgery. For the new kidney to work well, blood needs to flow through it smoothly. Sometimes, small blood clots can form in the tiny blood vessels of the new kidney, which can be a serious problem and stop the kidney from working as it should. To prevent this, doctors often prescribe a special medicine called enoxaparin, which is a blood thinner.
The OPTI-TREX study is focusing on how to give this enoxaparin medicine. The main idea is that every child is different, and the amount of medicine they need can vary. This study wants to find a very precise way to adjust the dose of enoxaparin for each child, so they get the perfect amount to prevent clots without causing other problems.
The goal is to make sure the medicine is in what scientists call the 'target range' in the blood. This means there's enough medicine to stop clots, but not so much that it causes too much bleeding. By finding this ideal dose for each child, the study hopes to improve how well new kidneys work after a transplant and reduce the risk of serious complications from blood clots.
Key takeaways
- The study helps doctors find the perfect dose of a blood-thinning medicine (enoxaparin) for each child after a kidney transplant.
- This precise dosing aims to prevent dangerous blood clots in the new kidney.
- It could help the new kidney work better and for longer.
- The study involves careful monitoring of medicine levels through blood tests.
- This research focuses on improving care for children who have had a kidney transplant.
Who may be eligible?
This study is for people who are 18 years old or older. The researchers are looking for both male and female participants.
Specifically, this study focuses on individuals who have recently received a kidney transplant. The aim is to study how a particular blood-thinning medicine works in this group to prevent specific types of blood clot complications.
- Are you 18 years old or older?
- Have you recently had a kidney transplant?
- Are you male or female?
- Are you able to participate in regular blood tests?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you would receive the blood-thinning medicine enoxaparin, which is routinely used after kidney transplants. The doctors in the study will be very carefully adjusting the dose of this medicine for you. This will involve regular blood tests to check how much of the medicine is in your blood, specifically looking at something called 'anti-Xa activity'.
The research team will use a special method to help them decide on the best dose for you based on these blood test results. You would continue to have these adjustments and blood tests as part of your initial treatment after the transplant. The study is focused on monitoring the medicine's level in your blood approximately 28 to 30 hours after you first start taking it. The total duration of your participation will depend on your hospital stay and follow-up after your kidney transplant, but the specific part related to this study's dose adjustment will be early on in your treatment.
Potential risks and benefits
Locations (1)
- —France
Common questions
What is enoxaparin?
Enoxaparin is a medicine that helps prevent blood clots from forming. It's often called a 'blood thinner'.
Why is this study important for children with new kidneys?
After a kidney transplant, blood clots can sometimes form in the new kidney. This study aims to find the best way to give clot-preventing medicine to help the new kidney work well.
Will I get special treatment if I join the study?
You will receive the standard medicine (enoxaparin), but the doctors will use a very precise method to adjust the dose specifically for you as part of the study.
What blood tests will be taken?
Blood tests will be taken to measure how much of the enoxaparin medicine is in your blood, which helps doctors adjust your dose.
Can I stop being part of the study if I change my mind?
Yes, you can choose to leave the study at any time, and it won't affect your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.